All In Biotech

Drug Trial Radar · NCT03268005

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)

Last checked: Nov 19, 2026Latest source record: Jan 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,264 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,264

Actual

Start

Sep 19, 2017

Primary completion

Jan 7, 2019

Study completion Jan 29, 2019

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Aug 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin aspart or NovoRapid®/ NovoLog® - which treatment you get is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day (all insulins will be provided in pens). The study will last for about 8 months (34 weeks).

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2

Interventions

  • Faster-acting insulin aspartDrug

    Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

  • Insulin aspartDrug

    Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

  • Insulin degludecDrug

    Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

  • MetforminDrug

    Only participants who took metformin before the study should take metformin tablets, same dose as before the study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycosylated Haemoglobin (HbA1c)Time frame: Week 0, week 16

Locations

167 sites in 18 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Concord, California

  • Novo Nordisk Investigational Site

    Fresno, California

  • Novo Nordisk Investigational Site

    Fullerton, California

  • Novo Nordisk Investigational Site

    Lancaster, California

  • Novo Nordisk Investigational Site

    Norco, California

  • Novo Nordisk Investigational Site

    Sacramento, California

  • Novo Nordisk Investigational Site

    Ventura, California

  • Novo Nordisk Investigational Site

    Walnut Creek, California

  • Novo Nordisk Investigational Site

    Denver, Colorado

  • Novo Nordisk Investigational Site

    Golden, Colorado

  • Novo Nordisk Investigational Site

    Waterbury, Connecticut

  • Novo Nordisk Investigational Site

    Boynton Beach, Florida

  • Novo Nordisk Investigational Site

    Bradenton, Florida

  • Novo Nordisk Investigational Site

    Fort Lauderdale, Florida

  • Novo Nordisk Investigational Site

    Miami, Florida

  • Novo Nordisk Investigational Site

    Tampa, Florida

  • Novo Nordisk Investigational Site

    Alpharetta, Georgia

  • Novo Nordisk Investigational Site

    Lawrenceville, Georgia

  • Novo Nordisk Investigational Site

    Roswell, Georgia

  • Novo Nordisk Investigational Site

    Honolulu, Hawaii

  • Novo Nordisk Investigational Site

    Chicago, Illinois

  • Novo Nordisk Investigational Site

    Peoria, Illinois

  • Novo Nordisk Investigational Site

    Springfield, Illinois

  • Novo Nordisk Investigational Site

    Valparaiso, Indiana

  • Novo Nordisk Investigational Site

    West Des Moines, Iowa

  • Novo Nordisk Investigational Site

    Topeka, Kansas

  • Novo Nordisk Investigational Site

    Lexington, Kentucky

  • Novo Nordisk Investigational Site

    Lexington, Kentucky

  • Novo Nordisk Investigational Site

    Rockville, Maryland

  • Novo Nordisk Investigational Site

    Waltham, Massachusetts

  • Novo Nordisk Investigational Site

    Worcester, Massachusetts

  • Novo Nordisk Investigational Site

    Henderson, Nevada

  • Novo Nordisk Investigational Site

    Las Vegas, Nevada

  • Novo Nordisk Investigational Site

    Nashua, New Hampshire

  • Novo Nordisk Investigational Site

    Northport, New York

  • Novo Nordisk Investigational Site

    West Seneca, New York

  • Novo Nordisk Investigational Site

    Asheville, North Carolina

  • Novo Nordisk Investigational Site

    Chapel Hill, North Carolina

  • Novo Nordisk Investigational Site

    Mentor, Ohio

  • Novo Nordisk Investigational Site

    Oklahoma City, Oklahoma

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.